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ABSTRACT
Epigenetic modification is another mechanism involved in the cancer development
besides classic mutations such as deletion. Aberrant promoter methylation and associated
chromatin modification have been frequently reported in various tumors of different
clinical stages. Hypermethylation has been frequently observed in tumor suppressor genes
and causes reduced transcripts of these genes. Hypomethylation also has been reported to
be involved in activation of oncogenes. Inactivation of the X chromosome and the
imprinting of gamete DNA depend on the methylation patterns in the promoter region.
Understanding methylation mechanisms could be helpful to diagnosis of early stage
tumorgenesis or offer molecular markers for detecting cancers.
Changes in methylation patterns based on human vulva pathological tissue type of four
genes have been studied in the current project. RASSF1A and DAPK-1 are tumor
suppressor genes. BRCA2 is considered highly associated with breast and ovarian cancer.
And H19 is a maternal imprinted gene. DAPK-1 and BRCA2 have been found to be
significantly hypermethylated in Lichen Sclerosis (LS) and Squamous Cell Carcinoma
(SCC). And RASSF1A has displayed an interesting methylation pattern in the post
transcription region, where the frequency of methylation significantly decreased from
normal tissue to LS tissue, but then dramatically increased to SCC. H19 failed to show any
changes in the methylation pattern with methods tested. This was most likely due to
interference of primer dimers by SYBR-green in the real-time PCR analyses.
Instead of using the same promoter sequence reported by previous papers, extended
estimated promoter regions and partial transcription regions were obtained from Genome

vii

Browser and additional CpG island sites have been studied in current project. Methylation
patterns have been detected that differ from the literature in these genes. These results may
provide more information to find a more precise active promoter region and epigenetic
involved sequences for future research.

viii

CHAPTER ONE
INTRODUCTION
1.1. Epigenetic Modification and DNA Methylation
The genetic information of an organism is written as a four-character code in DNA,
and is highly regulated and organized. However, epigenetic modification may change the
phenotype of a cell without altering its genotype, and that type of modification may also be
heritable. DNA methylation associated with histone modification is the only known type of
epigenetic modification essential in controlling gene expression under normal
circumstances in human and mammalian cells (Biel et al. 2005).
DNA methylation in eukaryotes always occurs at the 5 position of cytosine residues
followed by a guanosine residue in a CpG dinucleotide configuration, but in some bacteria
cells, methylation also takes place at adenine residues (Singal and Ginder 1999). Once
cytosine residues have been methylated, accidental deamination leads to the conversion of
methylcytosines to thymine residues which challenge DNA repair mechanisms (Antequera
and Bird 1993). Therefore, the frequency of CpG normally is pretty low throughout the
entire genome, representing only one base in around 1 per 50-100 (Feltus et al. 2003).
Approximately 70% to 80% of the CpG sites contain methylated cytosines in most
vertebrates, including humans (Bird 1995).
CpG islands are regions that are unusually rich in CpG sequences which range from
0.5 to 5 kb in length and occur on average every 100 kb with distinctive properties (Bird
1992). These regions are mostly unmethylated, GC rich (60% to 70%), and have a ratio of
CpG to GpC of at least 0.6 (Cross and Bird 1995). There are at least 29,000 such regions in
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the human genome, many of which reside in the 5’end of genes (Feltus et al. 2003).
Chromatin contained in CpG islands is generally heavily acetylated, lacks histone H1,
includes a nucleosome-free region which may allow or be a consequence of, the interaction
of transcription factors with gene promoters (Singal and Ginder 1999). Each gene builds its
own methylation pattern through specific methyltranferases and maintains its pattern
through mitosis. Aberrant methylation in the promoter regions of genes interferes with gene
expression and may be involved in many human diseases. Figure1.1 shows the biochemical
pathways for cytosine methylation, demethylation, mutagenesis of cytosine and 5-mC and
the enzymes involved in those pathways.

1.2. Functions of DNA Methylation
1.2.1 Roles in Gene Expression
1.2.1.1 Regulating Gene Expression
Experiments have shown that DNA methylation in the promoter region is related to gene
transcriptional repression and gene silencing. Although the real mechanism of how DNA
methylation results in gene silencing is still unclear, three possibilities have been proposed.
First, DNA methylation might directly interfere with the binding of specific transcription
factors to their recognition sites in their respective promoters (Tate and Bird 1993).Second,
it might cause the direct binding of specific transcriptional repressors to methylated
DNA(Rountree and Selker 1997). Lastly, it also might alter chromatin structure such as
deacetylation of the core histones H3 and H4 (Singal et al. 1997). However, whether
methylation is a primary control mechanism or a secondary effect, gene silencing is still an
important issue in human disease that needs to be addressed (Singal and Ginder 1999).

2

Figure1.1. Schematic representation of the biochemical pathways for cytosine methylation,
demethylation, and mutagenesis of cytosine and 5-mC (modified figure from Singal and
Ginder 1999).

1.2.1.2 Involved in Cancer (Carcinogenesis)
The patterns of DNA methylation are gene-specific, and tissue specific, so that a
unique set of proteins are only expressed to perform functions specific for a certain type of
cell. Therefore, DNA methylation patterns play a critical role in silencing specific genes
during development and cell differentiation (Singal and Ginder 1999). Numerous studies
have shown that aberrant methylation patterns in the promoter regions are among the
earliest and most common events in tumorigenesis. Activation of proto-oncogenes through
hypomethylation, transcriptional

inactivation
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of

tumor-suppressor

genes

through

hypermethylation, and defects in chromosomal segregation due to failure of de novo
methylation may all contribute to neoplasia (Singal and Ginder 1999).
Hypomethylation may be an important etiological component of cancer development.
Experiments have shown that hypomethylation is involved in gene activation, repetitive
elements de-repression, and chromosomal instability (Scarano et al. 2005). Global
hypomethylaiton was the first epigenetic abnormality to be identified in cancer cells (Scarano
et al. 2005). Experiments have also shown that promoter hypomethylation is associated with
cancer by activation of expression of normally silenced genes such as oncogenes (Chen et al.
1998). H-ras which regulates signal transduction is an important example of a
hypomethylated oncogene (Feinberg and Tycko 2004).
Hypermethylation is opposite to hypomethylation which refers to the increasing level of
methylation. Since aberrant promoter hypermethylation could inactivate normally expressed
genes, it contributes to silencing of tumor suppressor genes (Singal and Ginder 1999).
Aberrant promoter hypermethylation has been found to be involved in almost all the
important steps of carcinogenesis: cell-cycle regulation, DNA repair, drug resistance and
detoxification, apoptosis, cell differentiation, angiogenesis and metastasis (Scarano et al.
2005). A lot of tumor suppressor genes such as retinoblastoma gene (Rb), p16, P53, VHL,
MLH1, and BRCA1 have been detected to be involved in transcriptional inactivation in
cancer cells (Lim et al. 2003). The retinoblastoma gene (Rb) was the first classic
tumor-suppressor gene to be detected with promoter hypermethylation (Lim et al. 2003). P16
is known as one of the most important cell cycle regulatory proteins, and hypermethylation
mediated inactivation of the p16 gene has been demonstrated in brain, breast, colon, head and
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neck, and non-small-cell lung cancer and in high grade non-Hodgkin's lymphoma (Baylin et
al. 1998). Mutations in the p53 tumor-suppressor gene occur in more than 50% of human
solid tumors (Greenblatt et al. 1994).

1.2.2 Genomic Imprinting and X Chromosome Inactivation
Genomic imprinting is a particularly important mechanism in mammals. Genomic
imprinting refers to the expression of a gene in the developing embryo being dependent on
the allele’s parental origin (Feinberg et al. 2002). Over 70 imprinted genes have been
identified in mammals so far (Murphy and Randy 2003). DNA methylation has been found
to be the most consistent difference between the alleles of an imprinted gene, accompanied
by differences in chromatin conformation, histone modification, replication timing and
recombination rate (Paulsen and Ferguson-Smith 2001).
The reason for imprinting has not been conclusively identified todate, but the most
prominent assumption is that this process is necessary for development and may somehow
regulate growth in the embryo and behavior after birth (Paoloni-Giacobino and Chaillet
2004). Another theory based on evolution proposes that imprinting reflects the competing
interests of the maternal and paternal genomes in the developing embryo (Murphy and
Randy 2003).
In mammals, the random inactivation of one X chromosome also occurs by
methylation and histone H4 deacetylation (Scarano et al. 2005). This pattern is initiated at
blastocyst stage, around the time of implantation, and is maintained in all somatic cells
throughout (Maxfield Boumil and Lee 2001).
Loss of imprinting (LOI) is the disruption of imprinted epigenetic marks through gain
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or loss of DNA methylation (Kaplan et al. 2003). Studies of LOI have shown it plays roles
in cancer. LOI of IGF2 is the most common event across the widest range of tumor types
including colon, liver, lung, and ovarian cancer, as well as Wilms’ tumor which is the
embryonic kidney cancer where LOI was first discovered (Robertson 2005). Research has
shown that imprinting plays a role in the development of disease. (Peterson and Sapienza
1993) reviewed various disease syndromes caused by aberrant imprinting. The best
characterized

syndromes

Beckwith–Wiedemann

related

syndrome

to

growth

(BWS)

on

and

behavioral

chromosome

11p

defects

are

and

the

Prader–Willi/Angelman syndrome (AS) on chromosome 15q.

1.2.3. Roles in Evolution
From prokaryote, to nonvertebrate eukaryotes and vertebrates, the size of the genome
has increased from a few thousand genes to greater than 30,000genes (Bird 1995). And
the frequency of methylation of cytosine occurs much less in invertebrates to none in some
species such as Drosophila (Singal and Ginder 1999). (Bird 1995) proposed that since the
greater the number of tissue specific genes, the greater the efficiency of gene transcription
required. Therefore, DNA methylation in vertebrates reduces the transcriptional noise
through a global repression, and thereby allows vertebrates to accumulate and selectively
use the extra genes that are crucial to their development. DNA methylation is also
considered as a type of cell self-defense system during evolution(Yoder et al. 1997). It can
inactivate the promoter of most viruses and transposons, including retroviruses and Alu
elements (Singal and Ginder 1999). In addition, specific endonucleases may recognize
foreign DNAs since they have a different methylation pattern from host cells, and thus
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destroy those exogenous DNA fragments (Yoder et al. 1997).

1.3. Enzymes Involved in DNA Methylation
The methyl group is transferred from S-adenosylmethionines (SAM) to the 5 carbon of
cytosine ring through the action of DNA methyltransferses (DNMT), and SAM is converted
to S-adenosyl-homocysteine (SAH) (Campbell and Szyf 2003). Figure 1.2 illustrates the
mechanism of DNMT methylation via the SAM pathway (Strathdee and Brown 2002). DNA
methyltransferases establish the methylation pattern through de novo methylation, and then
maintain the specific pattern after semi-conservative DNA synthesis (Bestor 2000).

Figure1.2. Mechanism of DNA methylation.5-Methylcytosine is produced by the action of
the DNA methyltransferases (DNMT 1, 3a or 3b), which catalyze the transfer of a methyl
group (CH3) from S-adenosylmethionine (SAM) to the carbon-5 position of cytosine.
(modified from Strathdee and Brown 2002) .

Three methyltransferases genes (DNMT1, DNMT3A, DNMT3B) and one candidate gene,
DNMT2, have been identified. DNMT1, the first one identified and cloned, is highly
conservative in eukaryotes, and responsible for maintaining DNA methylation patterns
during DNA replication (Figure1.3) (Robert et al. 2003). It plays essential roles in
X-inactivation, genomic imprinting and genome stabilization (Bestor 2000). DNMT3A and
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DNMT3B are essential for de novo methylation and play important roles in normal
embryonic development and disease such as ICF syndrome (Okano et al. 1999). DNMT2 has
been identified in human and mouse which appears to lack the large N-terminal regulatory
domain common to other eukaryotic methyltransferases (Yoder and Bestor 1998). Recent
studies also have suggested aberrations in DNA methyltransferase activity in tumor cells
(Singal and Ginder 1999).
Besides methyltransferases, another enzyme called demethylase has been proposed to
direct the removal of the methyl group from methylated CpG (Bestor, 2000). However, no
demethylase enzyme or gene has been identified or isolated to date.

Figure1.3: Inheritance of the DNA methylation pattern.The original methylation pattern is
maintained through mitosis The maintenance methylase can methylate only the CG
sequence paired with methylated CG. The CG sequence not paired with methylated CG
will not be methylated.
(modified from www.web-books.com/MiBio/Free/ch7F2.htm)
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1.4. Causes of Aberrant Methylation
Disruption of normal DNA methylation patterns may occur as a consequence of
exposure to toxic agents, disease processes, and/or nutritional deficiencies.
Along with dietary factors, aging, chronic inflammation, viral infection, and exposure
to epimutagens all may cause aberrant methylation (Ushijima and Okochi-Takada 2005).
Among those, aging, chronic inflammation, viral infections, chemicals including nickel,
butyrate, and arsenic can induce aberrant methylation. Folate deficiency, choline deficiency,
and 5-aza-2’-deoxycytidine (5-zaz-dC) and its derivatives cause hypomethylation(Ushijima
and Okochi-Takada 2005).
Folate is a water soluble B vitamin and an important mediator in methyl group
metabolism (Kim 1999). 5-Methyl-terahydrofolate is a precursor of SAM and is the
primary methyl donor for most biological methylations (Sohn et al. 2003). A lack of folate
could increase the risk of cancer (Trasler et al. 2003).

1.5. Studies of Epigenetic Instability
Since DNA methylation is involved in gene regulation, evolution, cancer development,
genetic imprinting and X chromosome inactivation, and it is also unlike mutational
inactivation. Methylation is reversible and demethylating agents and inhibitors of histone
deacetylases could be used in clinical trails, knowing the mechanism of DNA methylation
may therefore have important clinical implications for the prevention and treatment of
human diseases. Studies of DNA methylation have been performed for several decades, but
the understanding of the whole puzzle is still very limited. The relationship between gene
regulation, DNA methylation, histone deacetylation, histone acetylation, methyltransferases,
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demethylases, methyl cytosine binding proteins, and the transcriptional activity of genes are
the necessary information to understanding epigenetic mechanisms and need to be fully
studied.
Epigenetic instability is measured by the detection of abnormal methylation of DNA
sequences, primarily promoter regions of oncogenes, tumor supressor and imprinting genes.
These procedures are based on PCR and MS-PCR (methylation specific-PCR) techniques
and gel electrophoresis, and occassionally include restriction endonuclease digestion. DNA
is treated with bisulfite to convert non-methylated cytidine residues to uridine (and then
thymidine upon PCR amplification), while the methylated cytidine (5-methyl-cytidine)
residues remain unchanged(Frommer et al. 1992). These procedures are well published and
the techniques are currently in use in our laboratory.
The present project will enable the study of the methylation status of genes from
normal skin to a preneoplastic disease (lichen sclerosus) state to squamous cell carcinoma.
I begun this work with PCR primer sets specific for methylated and unmethylated
sequences that are reported in the literature for each gene. New primers were designed
where necessary for the development of a more sensitive DNA methylation assay.
Methylation Specific PCR is used to distinguish methylated from unmethylated DNA in
this assay.

1.6. Gene Selection
Four genes were chosen for methylation analyses: DAPK- 1, RASSF1A, BRCA2 and
H19. Numerous publications in the literature have demonstrated the common occurrence of
hypermethylation of tumor suppressor genes in diagnosed cancers(Looijenga et al. 1997;
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Dammann et al. 2000; Reddy et al. 2003; Robertson 2005). But no one has verified the
status of those methylation changes early in the tumorigenic process of skin squamous cell
carcinoma (SCC). RASSF1A and DAPK-1 have been reported to be hypermethylated in
cancers, and are studied here to for their methylation status in skin cancers. Although H19
is an imprinted gene, no one has reported it being hypomethylated in human cancer.
BRCA2 has been reported to be involved in breast cancer, but the methylation status in skin
cancers has not been reported yet.

1.6.1 RASSF1A
The RASSF1 gene locus spans about 11,151 bp of the human genome which includes
eight exons, and differential promoter usage and alternative splicing generated seven
isomers (A-G) (Agathanggelou et al. 2005). RASSF1A is located at the 3p21.3 locus and is
considered to be a tumor suppressor gene which is frequently inactivated by epigenetic
events rather than classic mutation/deletion events (Vos et al. 2004; Agathanggelou et al.
2005). RASSF1A has been reported to be involved in apoptotic signaling, microtubule
stabilization and mitotic progression (Dammann et al. 2005). However, the precise
mechanisim of how RASSF1A protein functions in cell cycle regulation and tumor
suppression remains unknown (Vos et al. 2004).
Abberant hypermethylation of the RASSF1A promoter region has been reported in a
number of human primary tumors (>90 PubMed entries) and was observed initially in lung
cancer (Dammann et al. 2000). Those tumors include epithelial origin tumors such as breast,
cervix, liver, small cell lung carcinomas, nasopharyngeal carcinomas, renal cell carcinomas,
prostate carcinomas, and non-epithelial origin tumors such as neuroblastomas (Spugnardi et
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al. 2003). Hypermethylation of the promoter region also has been detected in body fluids
including blood, urine, nipple aspirates, sputum and bronchial alveolar lavages (Dammann
et al. 2005). Therefore, detection of aberrant RASSF1A methylation may serve as an early
diagnostic and prognostic marker for cancer.

1.6.2 DAPK1
Death-associated protein kinase 1 (DAPK1) is located in 9q34.1, and it is a 160-kDa
calcium/calmodulin-dependent

serine-threonine

kinase.

It

is

required

for

γ

interferon-induced apoptosis and is considered to be a tumor suppressor gene (Lehmann et
al. 2002). Previous studies have shown that treatment with 5-aza-2’deoxycytidine (a
demethylation reagent) on non-expressing cell lines resulted in expression of DAPK-1 gene
product, which suggested epigenetic invovlment (Katzenellenbogen et al. 1999). Numerous
studies have shown silencing of DAPK due to promoter hypermethylation plays role in lung,
esophageal, head and neck, prostate, bladder, gastric, and B-cell malignancies including
B-cell lymphoma, multiple myeloma, and Burkitt’s lymphoma (Reddy et al. 2003).
However, the timing of DAP-kinase inactivation by methylation during tumor development
has not been established (Pulling et al. 2004).

1.6.3 H19
H19 is the first human gene recognized to be paternally imprinted where the paternal
allele is inactivated through methylation (Brannan et al. 1990). It is located in chromosome
11p15.2 in both mice and humans within a cluster of at least five imprinted genes,
including IGF2 (Zemel et al. 1992; Morison et al. 2001). IGF2 and H19 are reciprocally
imprinted and coordinately regulated by an intergenic imprinting center and a common
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enhancer region (Kopf et al. 1998). IGF2 is an autocrine growth factor with an important
role in many types of cancer, and H19 is a non-coding RNA of unknown function with
growth suppressive properties, possibly functions as a tumor suppressor or oncofetal gene
(Hao et al. 1993). Loss of imprinting (LOI) of H19 has been observed in human
malignancies, including lung cancer (Kaplan et al. 2003). But it is also interesting that
up-regulation of H19 without LOI was found in the airway epithelium of cigarette smokers
(Kaplan et al. 2003). H19 is normally expressed during embryogenesis at high levels in
many organs (Lustig et al. 1994). In humans, there is biallelic expression of H19 in the
placenta at <10 weeks of gestation, but expression becomes monoallelic after 18-20 weeks
(Zhang and Tycko 1992). In adults, H19 expression remains monoallelic, with expression
primarily in skeletal muscle, thymus, heart, and lung (Looijenga et al. 1997).

1.6.4 BRCA2
BRCA1 and BRCA2 are two breast cancer susceptibility genes which have become
integrated into the practice of clinical oncology (Narod and Foulkes 2004). BRCA1 is
located at chromosome17q21, and BRCA2 is located at 13q12.3 (King MC 2001).
BRCA1 plays roles in DNA repair, cell-cycle-checkpoint control, ptotein
ubiquitylation and chromatin remodeling (Scully and Livingston 2000). However, BRCA2
is only known to be involved in homologous recombination (Narod and Foulkes 2004).
Hypermethylation of the BRCA1 promoter has previously been shown to cause reduced
mRNA expression in both breast and ovarian cancer (Chan et al. 2002), but
hypomethylation of the BRCA2 promoter region has been demonstrated in sporadic
ovarian cancer (Chan et al. 2002). No paper has report hypermethylaiton of BRCA2
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associated with reduced mRNA expression yet. Studies have found high frequencies of
hypermethylation of BRCA1 and hypomethylation of BRCA2 occurred within the same
specimens, so both of them may be important in the development of sporadic ovarian
cancer (Chan et al. 2002).

1.7. Pathological Types of Skin
1.7.1 Lichen Sclerosus (LS)
Lichen sclerosus (LS) is a chronic inflammatory dermatosis that is not contagious (Boms
et al. 2004). Any skin may be involved but the most common site is the genitalia which
represents around 85% to 98% of cases (Oyama et al. 2004). It has been reported that LS
affects women 6 to 10 times more often than men (Arican et al. 2004). The affected skin is
often itchy, usually white and sometimes with fine, crinkling texture (Arican et al. 2004). As
the condition progresses, bruising and pain may occur (Arican et al. 2004). Although it is still
not fully understood what causes lichen sclerosus (LS), it is generally thought that it is not
caused by a virus, bacteria, or fungus but something else entirely. Patients who with untreated
disease have an increased risk of a skin cancer of the involved areas, which amounts to
around 5% of cases that progress to malignancy most frequently squamous cell carcinoma
(Oyama et al. 2004).

1.7.2. Squamous Cell Carcinoma
American Academy Dermatology (http://www.aad.org/) states that

squamous cell

carcinoma (SCC), the second most common skin cancer after basal cell carcinoma, afflicts
more than 250,000 Americans each year. It arises from the epidermis and resembles the
squamous cells that comprise most of the upper layers of skin and may occur on all areas of
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the body including the mucous membranes. SCC is mainly caused by UV light
(http://www.skincancer.org/). Squamous cell carcinomas usually appear as crusted or scaly
patches on the skin with a red, inflamed base, a growing tumor, or a non-healing ulcer
(http://www.aad.org/). SCCs are usually locally destructive but if it left untreated, it eventually
penetrates and invades the underlying tissues. In a small percentage of cases, SCCs spread
(metastasize) to distant tissues and organs. When this happens, SCCs can be fatal
(http://www.skincancer.org/).
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CHAPTER TWO
MATERIAL AND METHODS
2.1 Sample Collection and Labeling
Human vulva tissues from over 100 patients were provided by Dr. Andrew Carlson of
Albany Medical College. Squamous carcinoma with adjacent lichen sclerosis and
surrounding normal tissues were obtained from each patient following therapy prescribed
radical vulvectomy; all of the surgically resected tissues were histologically analyzed.
Normal tissues from patients with no apparent vulva ailment were also collected and used
as uninvolved sample controls. Specimens were collected under approved IRB protocols
with informed consent from all surgical patients. Tissues were separately labeled and
packed based on the histological types and patients. Then tissues specimens were shipped
on dry ice and stored at -80 °C until further analysis.
Letter “CW” were assigned to samples from individuals with histological types associated
with cancer (SCC), lichen sclerosis (LS), and normal adjacent tissues. The number after
“CW” represents the patient’s number. A different number refers to different individual. The
sub-grouping (last number in the sequence) is an identifier used to discriminate multiple
tissues taken from one patient.

2.2 Genomic DNA Preparation
Two different DNA extraction procedures were used to purify DNA from samples. The
first one was a standard phenol and choloroform extraction protocol which is a universal
technique and the details are listed in appendix A. Equal volume phenol and choloroform are
used to remove proteins (e.g., Dnases and other enzymes) and followed by precipitation of
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the DNA. Details of this protocol have been listed in appendix A. The second procedure
utilized the QIAamp DNA Mini Kit (Qiagen Inc., Chatsworth, CA) which makes the
extraction of DNA more efficient. In both protocols, DNA are precipitated by cold ethanol
and re-suspended in 1x TE buffer (Appendix B). The isolated DNAs were quantified through
a Beckman DU-64 Spectrophotometer.

2.3 Bisulfite Treatment of Isolated DNA
The purpose of this published procedure (Frommer et al. 1992) is to convert
unmethylated Cytosine to Uracil, without changing the methylated cytosine residues (Figure
2.1). After the modification, the two daughter strands of modified DNA will no longer be
complementary to each other. For the present study, approximately 1-2µg of DNA was
denatured in NaOH and modified by sodium bisulfite treatment following the protocol of
(Herman et al. 1996). Then the modified DNA samples were purified by using the Wizard
DNA purification kit (Promega), treated again by NaOH and precipitated by cold ethanol.
Dry DNA pellets were stored at -80°C and re-suspended in 20µl of 0.1X TE. Details of this
protocol have been listed in appendix C.

2.4 Methylation Specific PCR
2.4.1 Gene Specific Sequences
Gene promoter sequences were originally obtained from published papers identified on
PubMed, but after comparison by BLAT (http://www.genome.ucsc.edu/cgi-bin/hgBlat), the
published sequences were found to be incomplete with modified mRNA sequences.
Therefore, Genome Browser( http://www.genome.ucsc.edu) was used to search the complete
gene sequences. Promoter sequences were estimated to be 1000bp upstream from the first
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exon of each gene.

Figure 2.1 The Mechanism of Bisulfite Treatment.
(modified from www.methods-online.net)

2.4.2 Methylation-Specific PCR Primer Design
Methprimer (http://www.ucsf.edu/urogene/methprimer/) was used to find out the regions
of CpG islands within estimated promoter sequences and partial cDNA sequence.
MethPrimer, which is based on Primer3, is a program designed for the production of MSP
primers (Li and Dahiya 2002).
Primers for RASSF1A and DAPK were originally chosen based on published papers
(Herman et al. 1996; Lehmann et al. 2002), but PCR amplifications lacked the required
specificity. Therefore, Methprimer was used to design primer sets for both methylated and
unmethylated sequences for all the four genes. Primers were designed within each CpG island
and incorporated at least 3 non-CpG cytosines in the original sequence to assure that
unmodified DNA will not serve as a template for the primers. The last three bases at the
3’-end of primers contained at least one CpG sequences. This provides optimal specificity
and minimizes false positives due to mispriming. Primers in the M (methylated) pair and U
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(unmethylated) pair also contained the same CpG sites within their sequence. Both M and U
sets of primers should preferably have similar Tm values, thus allowing the two PCR
reactions for each sample to be carried out simultaneously in the same PCR reaction under
the same annealing conditions.

2.4.3 Methylation Specific PCR Amplification
After bisulfite conversion, the modified DNA was ready to be used as a template for U
and M PCR analyses. Methylation PCR (M primer set) was designed to be specific for DNA
originally methylated for the gene of interest, and unmethylation PCR (U primer set) was
designed to be specific for DNA originally unmethylated. PCR products were separated on
2% agarose gels and the bands were visualized by staining with ethidium bromide using UV
fluorescence. The presence of a band indicates the presence of unmethylated, and/or
methylated alleles, in the original sample. MSP was very sensitive, and permitted the analysis
of small and heterogeneous samples, including paraffin-embedded material.
Twenty µl PCR amplifications were performed under the following conditions: 2µl of
modified DNA (50-100ng), 1µl of primers (final concentration is 0.125µM), 10µl of
TAKARA Real Time Pre-Mix (Takara Mirus Bio) and 7µl of water. All reactions were
subjected to the an initial denaturation step at 95ºC for 30 seconds. If the annealing
temperature >=60ºC, then a shuttle PCR was performed where each cycle has a 5 seconds
denaturation step at 95ºC followed by a 34 seconds primer annealing step at the specified
annealing temperature. If the annealing temperature is <60ºC, then after 5 seconds
denaturation step at 95ºC, a 20 seconds annealing step at the specified annealing temperature
is performed followed by a 30 seconds extension step at 72ºC.
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2.4.4 Real-time Methylation Specific PCR
The real-time PCR system is based on the detection and quantitation of the signal of a
fluorescent reporter which increases in direct proportion to the amount of PCR product in a
reaction at each cycle (Lee et al. 1993; Livak et al. 1995). The higher the starting copy
number of the nucleic acid target, the sooner a significant increase in fluorescence is
observed. The cycle number at which the fluorescence emission exceeds the fixed threshold
is defined as CT. Therefore, the more initial target templates present, the smaller the CT value
is. The difference between the CT of each sample indicates the difference between the initial
sample size or initial copy number.
Since partial hypermethylation or partial hypomethylation could not be detected by
traditional MS-PCR, real-time MS-PCR turns out to be the appropriate way to detect the
difference between initial amount of unmethylated amplicons and methylated amplicons
quantitively.
SYBR green was used as a reporter dye in the real-time PCR. It is a fluorogenic minor
groove binding dye that exhibits little fluorescence when in solution but emits a strong
fluorescent signal upon binding to double-stranded DNA (Morrison et al. 1998). The
disadvantage of this reporter dye is that none-specific PCR products interfere with the target
signal. But SYBR green is a less expensive reagent which is ideal if there is no non-specific
PCR product.
Real-time PCR amplifications were performed by using ABI PRISM 7000 Real- PCR
system. 2µl of modified DNA (50-100ng), 0.6µl of primers (final concentration is 75nM),
10µl of ABSOLUTE™ QPCR SYBR® Green Mixes (ABgene Inc., USA) and 7.4 µl of
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water end up 20 µl as total per reaction. All reactions were subjected to the an initial
denaturation step at 95ºC for 15 minutes. The parameters for the rest of the cycles are same
as those described in Methylaiton Specific PCR.
A dissociation curve analyses starting at 60ºC has to be performed after real-time PCR
amplification steps. Dissociation curve is used to detect the presence of non-specific
amplification products in SYBR-green real-time PCR.
Three replicates of each DNA sample were analyzed at the same time. Unmethylation
and methylation real-time PCR were also carried on the same plate at the same time. The
average value of CT from each sample was calculated and compared. Table 2.1 lists primer
names, sequences, product base pair size, annealing temperatures, and sources.

2.5 Reagents
The TAKRA polymerase (Premix Ex TaqTM) was purchased from Takara Mirus Bio
which is a newly-formed joint venture between Takara Bio Inc. and Mirus® Corporation.
ABSOLUTE™ QPCR SYBR® Green Mixes were purchased from ABgene Inc., USA. The
primers used in the assay were purchased from Integrated DNA Technologies, INC (IDT).
Primers were diluted upon arrival with 1X TE buffer to 100µM as stock. Primer stocks were
further diluted to 2.5 µM before use in PCR anaylses. Unmethylated and methylated controls
were purchased from Serologicals Corporation (United Kingdom). All reagents were stored
in a standard freezer at -20oC and thawed on ice before use.

2.6 Statistics Analysis
For MSP, Chi-Square Test was used to determine if the methylation patterns were
significantly different between the tissue types. For real time PCR, one way ANOVA was
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performed, and tissue type was considered as fixed effects. This statistical analysis
determined if different pathological types had significant differences regarding to the
methylation pattern. A p value which is equal to or less than 0.05 is considered to
demonstrate a statistically significant difference between pathological types.
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Table 2.1

Primer sets of all the genes

Primer Set
(1,2)RASSF1A-U
(1,2)RASSF1A-M
(2)RASSF1A-U
(2)RASSF1A-M
(1)DAPK1-U
(1)DAPK1-M
(2)DAPK1-U
(2)DAPK1-M
(4)DAPK1-U
(4)DAPK1-M
(1)BRCA2-U
(1)BRCA2-M
(2)BRCA2-U
(2)BRCA2-M
(4)BRCA2-U
(4)BRCA2-M
H19-U
H19-M

Forward Primer

Reverse Primer

5’ 3’

5’ 3’

TAAATTGGATTAGG

CCCAAAATCCAAACT

AGGGTTAGGGTT

AAACAACAAA

ATCGGATTAGGAG

CCAAAATCCAAACTA

GGTTAGGGTC

AACGACGA

GGTAGTTGGTTTTT

ACCTAATCCTCAAAA

GGTTGTGGTTATT

ACTATCCCCAC

TGGTTTTTGGTCGT

TCCTCGAAAACTATCC

GGTTATCGT

CCGC

AGTATTTTGGGAGG

TCCCCAATAACTAAA

TTTAGGTGG

ACTACAATCAC

TTAGTATTTTGGGA

TCCCCAATAACTAAA

GGTTTAGGC

ACTACAATCG

AGTTGTGTTTTTGTT

CCACCTTAACCTTCCC

GTTGTTTTGG

AATTACTCA

TTAGTTGTGTTTTC

GCCTTAACCTTCCCAA

GTCGTGTTTC

TTACTCGA

GAGATTGATGTATG

TACCAAATTCCTCACC

AGGGGGTTAT

AATATCATA

GAGATTGATGTATG

AATTCCTCGCCGATAT

AGGGGGTTAC

CGTA

AATTATTTGATTTTT

ACAAAATTTCACTCTT

GGAGGTGG

ATAACCCAAA

GAGAATTATTTGAT

GAAATTTCGCTCTTAT

TTTTGGAGGC

AACCCG

GTTTTTGAAATTAG

CAAAAACAAAAAAAC

GTGGTAGAGGTGG

AAAAAACCACAAC

AGTTTTTGAAATTA

AAAAACAAAAAAACA

GGCGGTAGAGGC

AAAAACCGCG

GATATGTTGATGGG

ATACCACTAACCACA

AATTATTAGGTG

TTAAACACTCAA

GATATGTTGATGGG

ATACCACTAACCACA

AATTATTAGGC

TTAAACACTCG

GTTTGGGAGAGTTT

TCCAATTAACCAAAC

GTGAGGTTGT

TTATACTAATCACCA

GGTTTGGGAGAGTT

CCAATTAACCGAACT

TGTGAGGTC

TATACTAATCACCG

Size

Annealing

bp

Temp( oC)

290

61

289

61

237

61

225

61

145

56

147

56

224

58

224

57

164

55

159

55

87

65

88

65

297

55

297

55

164

61

164

61

187

58

187

58

1: The number in the ( ) indicates the location of the CpG island. For example: (1) indicates
the first CpG island which is located furthest away from the start codon of the gene.
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CHARPTER THREE
RESULTS
3.1. Sequence Alignment
In order to design primers at the CpG islands at promoter regions of each gene, it is
necessary to find the correct 5’ upstream transcription region (UTR) and partial coding
region first. Sequences from previous published papers were all based on mRNA sequence
from genebank. Published primers for RASSF1A (genebank NM_007182) and DAPK1
(genebank X76104) were initially tried, but the results of MSP were very inconsistent. New
primers sets were designed for these two genes as noted below. The first set of primers
designed for BRCA2 were based on the genebank DNA sequence (NM_000059), but failed
to provide the expected MSP bands. In order to solve this MSP primer design, a new
approach to designing MSP primer sets was needed. Genome Browser is a new online
genomic database which launched on 2004 with more complete genomic sequences and
functions, which could specify the sequence of exon, intron and start codon. UTG and
partial coding sequence alignment between genebank and Genome Browser were
performed in order to obtain a more accurate sequence for each gene.
Alignment for RASSF1A (Fig 3.1.a) using genebank sequence NM_007182 provided
the complete sequence of exon1 on chr3:50342221-50353371. Alignment for RASSF1A
(Fig 3.1.a) showed NM_007182 provided the complete sequence of exon1 on
chr3:50342221-50353371. Genome Browser shows DAPK has three isomers which are
DAPK1, DAPK2 and DAPK3. DAPK1 is located at

chr9:87341696-87553100

(CR749834), DAPK2 is located at chr15:61986288-62125574 (NM_014326), and DAPK3
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is located at

chr19:3909451-3920826 (NM_001348). Previous published papers

regarding methylation status of DAPK were based on gene bank X76104. Alignment for
X76104 showed that these sequences were actually at chr9 which meant it actually refered
to DAPK1. But alignment for DAPK1 showed that UTG sequence from X76104 was split
by intronic sequences (Fig3.1.b). Part of the sequence was in the first intron, and the rest of
the sequence was in the second exon which resides on chr9:87,341,697-87,553,100.
Alignment for BRCA2 sequences also demonstrated that the UTR sequences from
NM_000059 are devided on chr13:31787617-31788610. Part of the sequence is on the
first exon, while the rest is on the second exon (Fig 3.3c). Sequences for H19 were taken
used from Genome Browser, because there was no specific UTR sequence provided by
genebank.

(a)

Figure3.1 a: Alignment of RASSF1A.b: Alignment of DAPK1. C: Alignment of BRCA2.
Matching bases in coding regions of cDNA from genebank and genomic sequences are
colored blue and capitalized. Matching bases in UTR regions of cDNA and genomic
sequences are colored red and capitalized. Grey highlighted sequences are exons.
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(fig.cont’d)
(b)
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(fig.cont’d)
(c)

3.2. RASSF1A
Agathanggelou et al (2005) mentioned actually there are two CpG islands are associated
with the promoter regions of RASSF1. The first and also the smaller of the two spans the
promoter region of RASSF1A (and RASSF1A, RASSF1E, RASSF1F, and RASSF1G). The
second CpG island encompasses the promoter regions for RASSF1B and RASSF1C. The
entire first exon of each RASSF1 transcript is contained within the CpG islands. Using
MethPrimer, two CpG islands were identified in the estimated promoter region and
extended regions. The first CpG island was located before the first exon and the second
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CpG island expanded from the end of the promoter region into and through Exon1 and
partway into Intron1 (Figure 3.2) .The size, start point and end point of each CpG island on
the input sequence are listed at table 3.1. Since there are only 8 bp apart, these two islands
could be considered as one which is concordance to the smaller one that Agathanggelou et
al. mentioned.

Figure 3.2: The distribution of CpG islands at RASSF1A.
Table 3.1. CpG islands of RASSF1A
Island 1
Island 2

Size(bp)
133
559

Start - End
795 - 927
935 - 1493

Two sets of primers were designed to study the methylation status of RASSF1A. The
first primer sets (both U and M primers) amplified the region across both islands but before
the start codon. A total of 8 samples were analyzed and were all found only unmehtylated.
However, the bands were not very clear and the results questionable.
The second sets of primers designs were positioned right after the start codon of
RASSF1A but within the second CpG island region. A total of 118 samples were analyzed
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and the results are listed in table 3.10 and figure 3.3.
Methylation was found in twenty three of fifty two (44.2%) samples of vulvar SCC and
eleven of twenty six (42.3%) normal tissues samples (Table 3.2). But there were only seven
out of forty (17.5%) lichen sclerosis tissues. The methylation of SCC specimens using the
RASSF1A primer was found to be significantly higher than lichen sclerosis tissues
(p=0.0067), but not significantly different from normal tissue (p=0.8717). Lichen sclerosis
was also significantly less methylated than Normal tissue (p=0.0270).

Figure3.3 Representative samples of MSP analysis of the RASSF1A gene on the 2nd CpG
island
Table 3.2. The methylation status for RASSF1A
Normal
LS
SCC

Unmethylated
15
33
29

Methylated
11
7
23

Total
26
40
52

Methylation (%)
42.3
17.5
44.2

3.3. DAPK1
Four CpG Islands were found in the DAPK1 gene sequence with the Methprimer
software. The first CpG island is located in the promoter region. The second and the third
CpG island are both located within the first inron. The fourth CpG island extends from the
end of Inron1 to almost the end of Exon2 (Figure 3.4). The size, start point and end point of
each CpG island are listed at table 3.3.
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Figure3.4: The distribution of CpG islands at Dapk1
Table3.3. The distribution of CpG islands of DAPK1
Size(bp)
Island 1
224
Island 2
1119
Island 3
238
Island 4
206

Start - End
403 - 626
1322 - 2440
2456 - 2693
2456 - 2693

Three sets of primers were designed for studying the methylation status of DAPK1
within the first, second and fourth CpG islands. Eight samples were analyzed for the first
CpG island region, and twenty samples were analyzed for the fourth CpG island region. All
of the samples showed both bands for unmethylation and methylation on both regions
(Figure 3.5).
A total of 107 samples were analyzed by MSP on the second CpG island (Table 3.10,
Figure 3.5). From table 3.4, hypermethylation was found in twenty three of fourty four
(52.3%) samples of vulvar SCC and eighteen of thirty seven (48.7%) lichen sclerosis
samples. But there were only six out of twenty six (23.0%) normal specimens found to be
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hypermethylated. The methylation of SCC specimens was found to be significantly higher
than adjacent normal tissues (p=0.0166), as was lichen sclerosis tissues compared to
normal tissues (p=0.0396). However, the occurrence of methylation in SCC samples was
not significantly different from lichen sclerosis samples (p=0.7452).

(a)

(b)

(c)

Figure 3.5 Representative samples of MSP analysis of the DAPK-1 gene. location: a)1st
CpG island, b)2nd CpG island, c)4th CpG island
Table 3.4. The methylation status of the second CpG island of DAPK1
Methylation (%)
Unmethylated Methylated Total
Normal
20
6
26
23.0
LS
19
18
37
48.7
SCC
21
23
44
52.3

3.4. BRCA2
Four CpG Islands were found in BRCA2 sequence using the Methprimer program
(Figure 3.6). The first CpG island is located in the promoter region and the second CpG
island extended from the end of the promoter region into and through Exon1 and partway
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into Intron1. The third and the fourth CpG islands are both located within Intron 1 (Figure
3.4). The size, start point and end point of each CpG island are listed at Table 3.5.

Figure3.6. The distribution of CpG islands at BRCA2
Table3.5. Distribution of CpG islands of BRCA2
Size(bp)
Start - End
Island 1
140
259 - 398
Island 2
496
836 - 1331
Island 3
127
1349 - 1475
Island 4
166
1616 - 1781
Three sets of primer sets were designed to study the methylation status of BRCA2
within the first, second and fourth CpG islands. Seven samples were analyzed for the first
CpG island region, and twenty three samples were analyzed for the fourth CpG island
region. All of the samples showed both unmethylation and methylation bands on both the
first and fourth CpG regions (Table 3.10, Figure 3.7). Fifteen samples for the second CpG
island region showed only unmethylation (Table 3.10, Figure 3.7).
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(a)

(b)

(c)

Figure 3.7 Representative samples of MSP analysis of the BRCA2 gene. location: a)1st
CpG island, b)2nd CpG island, c)4th CpG island
Since regular MSP could not detect changes in the methylation level of Brca2, real-time
PCR was performed using the fourth CpG island primer set. Three replicates of each sample
for both U and M PCR were performed.
Dissociation curves starting at 60 oC were performed after 40 cycles to ensure there were
no non-specific PCR products. A single product would show a single sharp peak at its melting
temperature, but non-specific products such as primer dimers would show another sharp peak
at its own melting temperature (Figure 3.8). Dissociation curves depend on PCR products’
GC content, size etc. Therefore, even two products with same size but different GC content
could be differentiated by dissociation cures which could not be seperated by regular
electrophoresis. The determination of dissociation curves is a necessary and powerful step
which should be included in SYBR-green real-time PCR.
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Figure 3.8. Dissociation curve for one replicate of sample 35-3 and blank
Twenty five samples were analyzed by real-time PCR using the same primer sets as
regular MS-PCR (Table 2.1).Only fifteen samples gave valid data due to the presence of
non-specific products (Table 3.9). Primer dimers tended to form when the initial
concentrations of DNA templates were low. For example, sample CW 70-5 (Figure 3.9), all
three replicates of the U reaction showed products and dimers, while only pure M Products
were observed in the same sample. This phenomena could be because there were not enough
unmethylated templates in the sample due to hypermethylation. Other samples had dimers in
both U and M reactions, which might because there were not enough templates left after
bisulfite treatment.
As mentioned in Methods, Ct value is the cycle number when the fluorescence light
produce by SYBR-green attached to products reached the threshold. The greater the initial
number of templates, the earlier the product fluorescence light would reach to the threshold.
The difference of the Ct value (Dct) between U and M PCR reactions from each sample would
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indicate if the methylation level of the original copy number increases or decreases (Figure
3.10).

Figure 3.9 Dissociation curve for one replicate of sample 70-5

Figure 3.10 Applification plot of sample CW 35-3.The Green line is the threshold, and the
cycle number that the Delta Rn reaches the threshold is the Ct Value for that reaction.
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Since the amount of fluorescence light is proportional to the total amount of the product,
and the PCR product size of U and M are same. Therefore, if we assume the reaction
efficiencies for both sets of primers are same, we can give an estimation of the proportion of
the initial unmethylated templates and methylated templates in a heterozygous cell. Using Ui
to represent the percentage of initial amount of unmethylated templates, Mi to represent the
percentage of initial amount of methylated templates, a and b represent the Ct value for U
reaction and M reaction respectively. By the time both reaction reached to threshold, the total
templates in each reaction should follow equation below:

Ui * 2a = Mi * 2b

(Equation 3.1)

U i + M i = 100

(Equation 3.2)

Therefore, we can find that the proportion of methylated templates is :
M

i

=

100
2

(b − a )

+1

(Equation 3.3)

Based on equation 3.3, we can estimate how much percentage of methylated templates and
whether it increases or decreases in each sample.
Three replicates of each sample were performed, but not every replicate gave a specific
product. Only data from those replicates that showed no non-specific products were used.
However, it was necessary to use at least two replicates for each sample to ensure accuracy.
Therefore, only fifteen samples had at least two replicates with pure products. Also, due to
experiment error, even those samples with all three replicates having specific products did not
have similar Ct values. Sometimes one of the Ct values would be different from the other two
replicates’ values. In this situation, only the two Ct values close to each other were chosen.
Means of Ct values, Dct values and M values of all the replicates for each sample and each
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type of reaction were calculated for final analysis (Table 3.6)
Table 3.6.The average values of each sample
Sample tissue
Average Average Average Average Average
type
Ct (M)
Ct (U)
Dct
% of U
% of M
14-7
N
26.0933 24.4700
1.6233 75.4954 24.5046
2b
N
23.9933 22.4033
1.59 75.0658 24.9342
30-2
N
25.1767 22.8633
2.3133 83.2507 16.7493
39-1
N
24.3733 22.2900
2.0833 80.9082 19.0918
40-4
N
26.0700 23.0867
2.9833
88.774
11.226
41-2
N
25.3467
22.735
2.6117 85.9394 14.0606
52-2
N
31.4350 30.0250
1.41
72.658
27.342
52-1
LS
25.1033
24.06
1.0433 67.3308 32.6692
52-6
LS
25.2400 23.8800
1.36 71.9641 28.0359
27-1
SCC
24.2400 22.9033
1.3367 71.6371 28.3629
35-3
SCC
28.3867 26.7633
1.6233 75.4958 24.5042
50-4
SCC
32.0833 30.6300
1.4533 73.2506 26.7494
50-7
SCC
30.9300 29.1400
1.79 77.5692 22.4308
63-1
SCC
28.7700 27.2100
1.56 74.6742 25.3258
91-2
SCC
26.5167 25.2550
1.2617 70.5685 29.4315
Least Square Means were calculated for the percentage of mehylation templates (M) and
the differences of the Ct values (Dct) were based on the tissue type (Table 3.7). ANOVA
analysis performed for both M and Dct based on the tissue type, and comparison between
each type of tissue were also performed (Table3.8, table 3.9)
Table 3.7 Estimated Least Squares Means of Dct and M
Standard
Estimated
Estimated
Tissuetype
Error (Dct)
M
Dct
N
2.0879
0.1651 19.7012
LS
1.2017
0.3088 30.3526
SCC
1.5042
0.1783 26.1341

Standard
Error (M)
1.7780
3.3263
1.9205

Table 3.8 Differences of Least Squares Means of Dct
TissuetypeStandard
Effect
Estimate
Df t Value
Pr>|t|
Tissuetype
Error
tissuetype LS_N
-0.8862
0.3502 12
-2.53 0.0264
tissuetype LS_SCC
-0.3025
0.3566 12
-0.85 0.4129
tissuetype N_SCC
0.5837
0.243 12
2.4 0.0334
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Table 3.9 Differences of Least Squares Means of percentage of methylation
TissuetypeStandard
Pr>|t|
Effect
Estimate
Df t Value
Tissuetype
Error
10.6513
3.7717 12
2.82
0.0153
tissuetype LS_N
4.2185
3.8409 12
1.1
0.2936
tissuetype LS_SCC
-6.4329
2.6171 12
-2.46
0.0301
tissuetype N_SCC
The results demonstrates that the value of Dct and percentage of methylated templates (M)
varied based on tissue type. The mean Dct value of normal tissues was significantly higher
than that of lichen sclerosis (LS) tissue (p=0.0264), and that of SCC (p=0.0334), but the mean
Dct values between SCC and LS were not significantly different (p=0.4129). The percentage
of methylated templates of normal tissue was significantly less than that of LS (p=0.0153),
and less than that of SCC (p=0.0301), but SCC and LS were not significantly different
(p=0.2936).
Real-time PCR was also performed at the first CpG island by using the same primers
for MSP listed at table 2.1, but no accurate results were collected since dissociation cures
indicated non-specific products constantly existed at the methylation PCR reaction no
matter what conditions were used. Gel electrophoresis also verified that primer dimmers
were the consistent non-specific products which interfered the results.

3.5 H19
H19 is located on chr11:1,972,984-1,975,280. Only one CpG island was found in the
gene sequence using the Methprimer program. The size, start point and end point of the
CpG island at input sequence are listed at table 3.8, shown in figure 3.11.
H19 is a maternal imprinted gene. Seven samples were tested with MSP and both U and
M bands were displayed in all cases. Therefore, real-time PCR was tested for the detection
of a change in each sample. Three different sets of primers were designed and tested in
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real-time PCR (Figure3.12). Unfortunately, dissociation curves showed there were
consistant primer dimmers in the products from every set of primers. Therefore, real-time
PCR with SYBR-green as reporter dye failed to detect changes in the methylation level for
H19.

Figure3.11. The distribution of CpG islands at H19

Table 3.8. CpG islands of H19
Size(bp)
Island 1
133

Start - End
795 - 927

Figure 3.12 Representative samples of MSP analysis of the H19 gene from one primer
sets.
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Table 3.9 Real-time PCR data of BRCA2
Sample
35-3
35-3
35-3
35-3
35-3
35-3
52-1
52-1
52-1
52-1
52-1
52-1
14-7
14-7
14-7
14-7
14-7
52-6
52-6
52-6
52-6
52-6
52-6
91-2
91-2
91-2
91-2
91-2
2b
2b
2b
2b
2b
2b
30-2
30-2
30-2
30-2
30-2
30-2
41-2
41-2
41-2
41-2
41-2

PCR type
U
U
U
M
M
M
U
U
U
M
M
M
U
U
M
M
M
U
U
U
M
M
M
U
U
M
M
M
U
U
U
M
M
M
U
U
U
M
M
M
U
U
M
M
M

TissueType
SCC
SCC
SCC
SCC
SCC
SCC
LS
LS
LS
LS
LS
LS
N
N
N
N
N
LS
LS
LS
LS
LS
LS
SCC
SCC
SCC
SCC
SCC
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N

Ct Value
27
26.66
26.63
28.36
28.44
28.36
24.07
24.04
24.07
25.11
25.02
25.18
24.5
24.44
26.17
26.02
26.09
23.78
23.87
23.99
25.14
25.27
25.31
25.14
25.37
26.43
26.48
26.64
22.51
22.25
22.45
23.97
23.9
24.11
22.93
22.88
22.78
25.16
25.13
25.24
22.43
23.04
25.44
25.38
25.22

(TABLE continued)

40

27-1
27-1
27-1
27-1
27-1
27-1
50-4
50-4
50-4
50-4
50-4
50-7
50-7
50-7
50-7
63-1
63-1
63-1
63-1
63-1
63-1
39-1
39-1
39-1
39-1
39-1
40-4
40-4
40-4
40-4
40-4
40-4
52-2
52-2
52-2
52-2

U
U
U
M
M
M
U
U
M
M
M
U
U
M
M
U
U
U
M
M
M
U
U
M
M
M
U
U
U
M
M
M
U
U
M
M

SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
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22.9
22.85
22.96
24.31
24.2
24.21
30.98
30.28
31.48
32.69
32.08
29.14
29.14
30.78
31.08
26.89
27.44
27.3
29.1
28.64
28.57
21.93
22.65
24.41
24.19
24.52
22.77
23.25
23.24
26.02
26.1
26.09
29.81
30.24
31.51
31.36

Table 3.10 MSP analysis of each sample
RASSF1A
Sample

DAPK1

BRCA2

H19

Type

CW 5-4

LS

CW 5-5

LS

CW 7-1

SCC

CW 10-1

SCC

CW 11-1

SCC

CW 12-1

SCC

CW 12-2

SCC

CW 12-4

SCC

CW 13-2

N

CW 13-4

N

CW 14-1

SCC

CW 14-2

SCC

CW 14-7

N

CW 16-2

SCC

CW 16-3

N

CW 17-1

SCC

CW 17-5

N

CW 17-6

LS

CW 18-1

SCC

CW 18-2

SCC

CW 18-5

N

CW 18-6

SCC

CW21-1

SCC

CW 21-3

LS

CW 22-1

SCC

CW 22-2

LS

CW 22-3

LS

CW 22-4

LS

CW 23-1

SCC

CW 23-3

N

CW 24-1

SCC

CW 25-1

SCC

CW 25-2

N

CW 26-2

SCC

CW 27-1

SCC

CW 28-1

SCC

CW 28-3

LS

CW 28-5

LS

CW 28-B

N

CW 29-1

SCC

CW 29-3

N

CW 29-4

LS

1st

2nd

1st

2nd

4th

1st

2nd

4th

1st

CpG

CpG

CpG

CpG

CpG

CpG

CpG

CpG

CpG

+

(TABLE continued)
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CW 29-5

LS

CW 29-6

SCC

CW 29-B

N

CW 30-1

SCC

CW 30-2

N

CW 30-3

LS

CW 30-5

LS

CW 31-2

LS

CW 31-3

LS

CW 35-2

LS

CW 35-3

SCC

CW 35-5

LS

CW 35-6

LS

CW 39-1

N

CW 39-3

N

CW 40-1

SCC

CW 40-2

SCC

CW 40-4

N

CW 41-1

SCC

CW 41-2

N

CW 43-1

SCC

CW 43-3

SCC

CW 43-4

SCC

CW 44-1

N

CW 44-2

SCC

CW 44-3

LS

CW 44-4

LS

CW 44-5

LS

CW 44-7

LS

CW 45-4

N

CW 45-5

LS

CW 46-3

LS

CW 46-4

LS

CW 46-5

LS

CW 46-6

LS

CW 46-7

LS

CW 47-2

SCC

CW 47-3

LS

CW 47-4

LS

CW 49-1

SCC

CW 49-3

SCC

CW 49-4

LS

CW 49-5

LS

CW 49-6

LS

CW 50-1

SCC

CW 50-2

SCC

CW50-4

SCC

(TABLE continued)
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CW 50-5

LS

CW 50-6

SCC

CW 50-7

SCC

CW 52-1

LS

CW 52-2

N

CW 52-6

LS

CW 53-1

LS

CW 53-2

LS

CW 53-3

LS

CW 57-1

SCC

CW 57-3

N

CW 60-1

N

CW 60-3

N

CW 61-1

SCC

CW 61-2

LS

CW 61-4

LS

CW 61-6

SCC

CW 62-1

N

CW 63-1

SCC

CW 63-2

SCC

CW 63-5

SCC

CW 64-3

SCC

CW 66-3

LS

CW 66-4

LS

CW 70-1

LS

CW 70-2

SCC

CW 70-3

SCC

CW 70-4

LS

CW 70-5

LS

CW 70-6

LS

CW 73-1

N

CW 89-1

SCC

CW 89-2

SCC

CW 91-1

SCC

CW 91-2

SCC

CW 93-1

SCC

CW 93-2

SCC

CW 97-1

SCC

CW 98-1

SCC

CW 98-4

SCC

CW 106-3

N

CW 108-1

N

Black cell: Sample both methylated and unmethylated
Grey cell: Sample only unmethylated
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CHAPTER FOUR
DISSCUSSION
4.1 General Discussion
The promoter regions of four genes have been studied for the methylation pattern in
normal vulva tissue to Lichen Sclerosis and Squamous Cell Carcinoma. Since the study
region for RASSF1A was designed after the transcription start codon, an interesting
methylation pattern was observed that was different from the majority of published results
(Burbee et al. 2001; Kim et al. 2003; Kuroki et al. 2003; Wang et al. 2004). The frequency
of methylation in RASSF1A significantly decreased (p=0.0270 ) from normal to LS, then
dramatically increase (p=0.0067) from LS to SCC. DAPK-1 was found to be significantly
hypermethylated in LS and SCC tissues, which is similar to previous studies on other
cancers (Katzenellenbogen et al. 1999; Lehmann et al. 2002; Tada et al. 2002). BRCA2 was
found to be hypermentylated in one of its CpG islands in both LS and SCC tissues. In the
analysis of the H19 gene, an imprinted gene, real-time PCR failed to detect changes in
methylation in diseased specimens. These results demonstrated that different methylation
patterns of RASSF1A, DAPK-1 and BRCA2 genes were detected based on different vulva
specimen disease states, and indicate that epigenetic events might be involved in or
associated with preneoplastic and early tumorigenesis.

4.2 RASSF1A
Although more than 90% of published papers listed on Pubmed have reported that
RASSF1A promoter hypermethyltion was associated with reduced mRNA expression in
tumors, the present studies display quite different results from previous studies. The
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frequency of hypermethylation of RASSF1A was found to be the same in vulva SCC and
normal tissue (44.2% and 42.3%, respectively). However, vulvar Lichen sclerosis (LS)
tissue only showed 17.5% methylation frequency. Methylation frequency significantly
decreased (p=0.027) from normal tissue to LS, and significantly increased (p=0.0067)
from LS to SCC. But there is no statistic significance between the Normal and SCC.
As shown in Figure 3.2, the CpG island studied spans the 5’UTG region through first
exon and extends past the transcription start codon. Since previous reports focused on only
the 5’UTG region, the present results help clarify progressive changes in methylation of
developing skin SCC. The majority of published reports used primers

located within the

CpG island located before the transcription start site. Primers for MSP which amplify the
region starting from the end the 5’ UTR and passing first exon but before the transcription
start codon were published by Burbee et al. (2001), and have been frequently used by other
papers. For examples,

Kuroki et al. (2003) found hypermethylation in esophageal

squamous cell carcinoma sample (52%) vs. only 4% in noncancerous tissues; Kim et al.
(2003) reported hypermethylation occurred 26% of lung squamous cell carcinoma and
Wang et al. (2004) reported hypermethylation was detected in 39% non-small cell lung
cancer tissue and only 3% in corresponding normal appearing lung tissues.
Methylation analyses of the CpG island located after the transcription start site of
RASSF1A has however also been reported. Spugnardi et al. (2003) assessed two different
regions of the RASSF1A CpG island located on both sides of transcription start codon to
study aberrant methylation. Region 1 was located upstream of the transcription start codon
and contained three Sp1 consensus binding sites, and the primers for the MSP were similar
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to those reported by Burbee et al. (2001). Region 2 was located within the first exon
immediately after the transcription start codon which is specific to the RASSF1A transcript
and similar to the current studied region. Hypermethylation of RASSF1A region 1 was
found in 41% of melanoma tumors, of which 33% of stage III melanoma patients, and 44%
of stage IV patients. Analysis of RASSF1A region 2 revealed aberrant methylation in 50%
of melanoma tumors with only 22% of stage III patients, but 56% of stage IV patients.
There was an increasing frequency of methylation through the tumor passage on region 2,
which is similar to my results showing the methylation frequency increase dramatically
from LS to SCC (17.5% to 42.3%). No methylation was detected in available normal skin
tissues or healthy donor peripheral lymphocytes, but Spugnardi et al. (2003) did not clarify
whether the normal tissues were normal adjacent tissue or normal non-adjacent tissue. 64%
and 82% of melanoma cell lines have been reported to be methylated in region1and region
2, respectively (Spugnardi et al. 2003). Hypermethylation was higher in RASSF1A region 2
in both cell lines and tumors, and RT-PCR revealed that samples where both regions were
methylated lacked RASSF1A gene expression (Spugnardi et al. 2003). Although at present,
the mechanisms of de novo methylation of tumor suppressor genes and other regulatory
genes are poorly understood, Spugnardi et al.

proposed that it is possible that the

hypermethylation event initiated in region 2 (exon 1) and then spread into region 1, the
upstream promoter region, which ultimately results in gene silencing.
Strunnikova et al. (2005) also investigated the methylation pattern of Human
mammary epithelial cells (HMEC) in different regions of the RASSF1A gene including a
region similar to that reported by Spugnardi et al. (2003) which contained three Sp1
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binding sites and the transcription start site (RA region), an upstream region to RA (U1)
and a downstream regions (D1). All of these regions were unmethylated in normal human
fibroblasts, blood leukocytes, and Hela cells. The RA region was completely unmethylated
in prestasis and stasis HMEC, and only methylated in postasis cells. Stasis is the state, in
which the normal flow of a body liquid stops, for example the flow of blood through
vessels or of intestinal contents through the digestive tract (Wikipedia contributors 2005).
However, both U1 and D1 which flanked the transcription initiation site exhibited frequent
methylation along with further increase in methylation in later passages of HMEC cultures.
RASSF1A was also dramatically silenced with increasing passages. My work has shown
that methylation dramatically increased from LS to SCC. My work also found that normal
tissues were also highly methylated. Unfortunatley, Strunnikova et al. (2005) did not report
the methylation pattern in the normal tissues. Based on the published results, Strunnikova
et al. (2005) also proposed there might be a spreading of de novo DNA methylation from
the methylated upstream and downstream regions into the RASSF1A CpG island promoter.
It appears that the primary control of gene expression may be due to methylation
status of the CpG island in the RASSF1A promoter region. However, understanding the
progressive changes in RASSF1A gene methylation in cancer development may require the
analysis of CpG islands before and after the start codon. The region that right before the
start codon which contains three Sp1 sites is frequently hypermethylated in human tumors
but unmethylated in normal tissues, while the down stream region is more frequently
unmethylated in normal tissue and the methylation increases with tumor development.
Current studies show that the methylation frequency significantly increases from LS to
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SCC at the down stream region, which is in concordance with previous studies, but it is
hard to explain that even normal tissues were as frequently methylated as SCC. And it is
also questionable that the de novo methylation spreading hypothesis proposed by
Spugnardi et al. and Strunnikova et al is valid.

4.3 DAPK-1
At the first and fourth CpG islands in the 5’ region of the DAPK-1 gene sequences,
MSP results showed both unmethylated and methylated bands were consistantly present in
all samples analyzed. This indicated that both alleles at these two regions might be
heterozygous by methylation. However, the second CpG island showed variation of
methylation patterns in different samples. Relating this information with Figure 3.3, it is
quite obvious that 5’ upstream region, and the regions slightly before exon2 might not be
involved in epigenetic events associated with gene expression process, while the first intron
is probably involved.
Hypermethylation of CpG islands in DAPK-1 has been frequently observed in various
types of human malignancies. The methylation results observed for DAPK-1 in the present
study were consistant with those seen in other studies. This study demonstrated DAPK-1
was found to exhibit a high frequency of promoter methylation in vulvar Lichen sclerosis
(LS) and SCC. These values for SCC and LS tissues were both found to be statistically
different from normal tissues. This relationship showing increasing methylation from
normal to LS and SCC suggests that epigenetic silencing of DAPK-1 is an early event in
vulvar neoplasia. These data correlate well with data from others studying SCC and other
cancers such as 53% in lobular invasive breast cancer, 9% in ductal invasive breast cancer,
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76.1% in nasopharyngeal carcinoma (NPC), 34%-35% in lung SCC, 29% in epithelium
bladder carcinoma and 84% in B-cell non-Hodgkin’s lymphomas, (Katzenellenbogen et al.
1999; Chan et al. 2002; Lehmann et al. 2002; Tada et al. 2002; Mittag et al. 2005)

4.4 BRCA2
Few papers about the study of aberrant methylation of the BRCA2 gene have been
published. Hilton et al. (2002) has reported that only 1 out of 12 (8%) tumors in ovarian
cancers lacked detectable BRCA2 mRNA showed hypermethylation, but all eight of the
tumors without detectable BRCA1 mRNA demonstrated BRCA1 promoter CpG island
hypermethylation. Dhillon et al. (2004) also reported a similar low occurrence of BRCA2
methylation in human primary tumors with only 1 out of 25 (4%) Granulosa cell tumor cell
lines hypermethylated. Both of these papers used the same primer sets for MSP, which
were located on the second CpG island as shown on in Figure 3.4, but neither of them
reported the methylation pattern in the normal tissues. These two papers also hypothesized
that the methylation pattern might not contribute to gene expression mechanism, although
other epigenetic events might be involved. It is possible that the region they studied might
not be involved in epigenetic instability, which also means it might not be the active
promoter region of BRCA2.
The second CpG island in the BRCA2 gene sequence extends from 5’ UTR, across the
exon1 and all the way down to intron1. Since the third island is only 18bp apart from the
second one, it was grouped together with the second CpG island. Only unmethylated MSP
patterns were observed at this region, suggesting that both alleles might be homozygous
unmethylated at this locus.
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The first CpG island is located in the 5’ UTR, while the fourth CpG island is in the first
intron but close to the transcription start codon. Both unmethylated and methylated patterns
were shown by MSP at the these two islands 100% of the time in vulva specimens. However,
partial variation of the methylation pattern could not be detected by regular MSP at these two
CpG islands. Real-time PCR revealed that the percentage of copy numbers of methylated
alleles statistically significantly increased from normal tissue (19.7%) to LS (30.4%) and
SCC (26.1%), but not between LS and SCC. If we assume both U and M primer sets have the
same reaction efficiencies, then the results would indicate that there exists an increase of
methylation of BRCA2 in the LS and SCC tissue specimens compared to adjacent normal
vulva tissue.
Another assumption is that the primer sets’ efficiency causes the difference of Ct value’s
which biased the data increasing the determined methylated templates in the cancer tissues.
However, from the results, approximately 80.3% of the alleles were unmethylated in the
normal tissue, but only 19.7% were methylated. It is less likely that this 60.3% difference can
be explained by the difference between primer sets’ efficiency.
Overall, from current studies, it appears that the fourth CpG island of BRCA2 is
frequently methylated in cancer tissue. Although inactivation of BRCA2 through promoter
hypermethylation has not been reported so far and gene expression level of BRCA2 has not
been tested in these vulva samples in the current studies, the change of hypermethylation
patterns still could be a molecular maker for the early stage occurrence of neoplaisa.
There is only one paper reporting the loss of methylation in BRCA2. Chan et al. (2002)
has reported a significant correlation between hypomethylation and overexpression of

51

BRCA2. Using enzyme-digested bisufite PCR inclusive of 31 CpG dinucleotides within
the promoter and 5’-UTR regions, hypomethylation of BRCA2 was observed in 16 out of
23 cases of sporadic ovarian cancer than in nontumor samples. Unfortunately, the exact
location of these CpG sites was not reported. Therefore, it is hard to locate the CpG sites in
the promoter region and compare their results with mine.
The current real-time PCR approach to these studies was unable to distinguish any
differences in methylation patterns on the first CpG island. But it is still important to find
out if any changes in methylation in the first CpG island correlate with changes at the
fourth CpG island. Gene expression analysis also needs to be done in order to clarify the
correlation between gene expression and methylation pattern in BRCA2.

4.5 H19
H19 is a maternally imprinted gene, and MSP results showed both unmethylation and
methylation bands for all the specimens studied, further supporting the heterozygosity of
the two alleles in this imprinted gene. Real-time PCR also failed to differentiate changes in
the methylation status of H19 in these studies. H19 might be a good indicator sequence if
variation in methylation patterns could be detected.

4.6 Real-time PCR
SYBR-green is a less expensive reagent and more easily used for real time PCR than
other approaches such as TaqMan and probes. But since it also reports the non-specific
products along with the amount of final products, the requirements for the primers’
efficiency are very high. Low amounts of template could also cause false negative results
which make it is hard to detect the copy number of unmethylated or methylated templates
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when hyper- or hypo-methylation has occurred.
TaqMan is another type of fluorescent reporter method commonly used in Real- time
PCR. With a matched probe, TaqMan only reports the specific amplicon even in the
presence of non-specific products. Based on my experience, it may be necessary to use
TaqMan for future studies in order to detect differences between the template copy
numbers of unmethylated and methylated templates in target genes.

4.7 Conclusion and Future Research
Although aberrant promoter hypermethylation and hypomethylation phenomenon in
tumor suppressor genes and oncogenes have been well published, the exact promoter
region and mechanism involved in the change of methylation pattern still remain unclear
for genes such as RASSF1A. Current studies investigated the CpG islands on a broader
region, and found there were different methylation patterns on different CpG islands even
in the same gene. Also since detecting aberrant methylation could be a diagnostic indicator
of cancer or a molecular marker for the early detection of cancer, it is important to know
the precise promoter region of each gene.
Promoter hypermethylation has been found in DAPK-1 and BRCA2 in current studies.
And an interesting methylation pattern after the transcription codon of RASS1A has also
been detected. No hypomethylation was detected in any gene in current studies. This
information will add to the literature regarding the relationship between aberrant
methylation patterns and early cancer prognosis, and may have potential clinical benefits in
cancer diagnosis, prevention and treatment.
Gene expression analysis needs to be performed in order to detect if there is any
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correlation between the methylation pattern found in current studies and gene expression
which can further support the involvement of epigenetic events in the transcription process.
RT-PCR, western blot analysis and chromatin immunoprecipitation (CHIP) could be used
to detect any change of gene expression, and the sequence associated with the transcription
factors involved in such epigenetic events.
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APPENDIX A
PHENOL AND CHLOROFORM EXTRACTION
PROCEDURE
Preparation of Genomic DNA from Mammalian Tissue
1. Excise an immediately mince tissue quickly and freeze in liquid nitrogen.
2. Grind 200 mg to 1g tissues with prechilled mortar and pestle, or crush with hammer to fine
powder.
3. Add 500 µl grinding buffer to the tissue in a 1.5 ml Eppendorf tube and vortex for
several minutes.
4. Spin the samples in a microfuge for 15 minutes.
5. Decant the solution and add 500 µl of lysis buffer and add 10 µl (6 Units) of proteinase K
to each sample. Digest at 37° for 12 hours.
6. Add 500 µl of phenol to each tube. Vortex briefly and centrifuge for 10 minutes.
7. Making certain not to disturb the interphase, transfer aqueous top solution to a clean
labeled tube and add 500 µl of chloroform. Vortex briefly and centrifuge for 10 minutes.
8. If a white precipitate is present at the aqueous/organic interface, reextract the
organic phase and pool aqueous phases.
9. Carefully remove the top aqueous phase containing the DNA using a 200 ulpipettor
and transfer to a new tube.
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APPENDIX B
ETHANOL PRECIPITATION OF DNA
1. Add 1/10 volume of 3M sodium acetate, pH 5.2, to the solution of DNA. Mix by
vortexing briefly or by flicking the tube several times with your finger.
2. Add 2 to 2.5 volumes of ice cold 100% ethanol. Mix by vortexing and place in crushed dry
ice for 5 minutes or longer. Alternately, the tubes can be placed at -80° for 1 hour or at
-20° overnight.
3. Spin 5 minutes in a microcentrifuge at high speed and remove the supernatant.
4. Add 1 ml of room temperature 70% ethanol. Invert the tube several times and
microcentrifuge as in step 6.
5. Remove the supernatant. Dry the pellet in a desiccator under vacuum or in a hood.
6. Dissolve the dry pellet in an appropriate volume of water or TE buffer (10mM Tris-HCL,
1mM EDTA), pH8.0
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APPENDIX C
BISULFITE TREATMENT OF DNA
This protocol was adapted from Frommer et.al.1992.
1. Dilute DNA (up to 2 mg) into 50 ml with distilled H2O.
2. Add 5.5 ml of 2M NaOH.
3. Incubate at 37°C for 10 minutes (to create single stranded DNA).
4. Add 30 ml of 10 mM hydroquinone (Sigma) to each tube, freshly prepared by
adding 55 mg of hydroquinone to 50 ml of water.
5. Add 520 ml freshly prepared 3M Sodium bisulfite (Sigma S-8890), prepared by
adding 1.88 gm of sodium bisulfite per 5 ml of H2O, and adjusting pH to 5.0 with
NaOH.
6. Assure that reagents are mixed with DNA.
7. Layer with mineral oil.
8. Incubate at 50°C for 16 hours (avoid incubations of much longer duration as
methylated C will start converting to T).
9. Remove oil.
10. Add 1 ml of DNA wizard cleanup (Promega A7280) to each tube and add mixture
to miniprep column in kit.
11. Apply vacuum (manifold makes this convenient).
12. Wash with 2 ml of 80% isopropanol.
13. Place column in clean, labeled 1.5 ml tube.
14. Add 50 ml of heated water (60-70°C).
15. Spin tube/column in microfuge for 1 minute.
16. Add 5.5 ml of 3 M NaOH to each tube, and incubate at room temperature for 5 minutes.
17. Add 1 ml glycogen as carrier (we use Boehringer glycogen, undiluted).
18. Add 33 ml of 10 M NH4Ac, and 3 volumes of ethanol.
19. Precipitate DNA as normal (overnight at -20°C, spin 30 mins), wash with 70% ethanol,
dry pellet and resuspend in 20 ml water.
20. Treat DNA like RNA (keep cold, minimize freeze/thaws, store at -20°C)
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